Oral and Maxillofacial Surgery Marketing Compliance: Wisdom Teeth, Implants, and Jaw Surgery
OMS marketing combines dental specialty board rules with surgical marketing framework plus specific considerations around sedation, implant outcomes, and jaw surgery claims.
Oral and maxillofacial surgery (OMS) is an ADA-recognized dental specialty. OMS practices market wisdom tooth extraction, dental implants, corrective jaw surgery, TMJ treatment, facial trauma, and reconstructive procedures. Each creates specific marketing compliance considerations.
Specialty recognition
OMS is an ADA-recognized dental specialty. Practitioners complete specific residency training. Marketing “oral surgeon” or “oral and maxillofacial surgeon” requires the specific residency training.
Dual-degree OMS (DDS/MD) credentialing should be accurately represented. “Dual-degree oral surgeon” marketing requires the actual dual degree.
Wisdom tooth marketing
Third molar extraction is one of the highest-volume OMS services:
- Pricing marketing should disclose what’s included (anesthesia level, consultation, x-rays, follow-up).
- Sedation options marketing should accurately represent what’s available and required for different patients.
- Pain-management claims need to be reasonable given typical post-extraction experience.
Dental implant surgical marketing
See dental implant marketing compliance post for the full framework. OMS-specific considerations:
- OMS can market specialty-level expertise in implant surgery as appropriate credentialing.
- Complex case marketing (bone grafting, sinus lift, zygomatic implants) needs accurate representation of complexity and outcomes.
- Restorative coordination with general dentists should be accurately represented.
Corrective jaw surgery (orthognathic)
Orthognathic surgery marketing considerations:
- Specific outcome claims (facial aesthetics, functional improvement, sleep apnea treatment) need substantiation.
- Insurance coverage for orthognathic varies; marketing should reflect actual coverage patterns.
- Before/after imagery for jaw surgery is highly-visible outcome content requiring particular framing care.
- Coordination with orthodontic treatment should be accurately represented.
TMJ and facial pain marketing
TMJ treatment marketing is a complex area:
- Specific treatment outcome claims vary in evidence support.
- Scope-of-practice considerations differ by approach (conservative care, injections, surgery).
- TMJ marketing has drawn FTC attention when specific outcome claims exceed evidence.
Sedation marketing
OMS practices offer varying sedation levels (local, oral, IV, general). Marketing considerations:
- State licensing for specific sedation levels varies.
- “Painless” absolute claims are unsubstantiable.
- “Sleep through your procedure” should accurately reflect the sedation level and associated risks.
Compliant OMS marketing framework
- Accurate specialty credentialing. OMS training, dual-degree if applicable, specific subspecialty interests.
- Consultation-forward complex case marketing.Individual evaluation as the entry point.
- Realistic recovery and experience framing.Most patients experience [typical recovery]; individual variation expected.
- Accurate insurance and pricing disclosure.What insurance covers, typical out-of-pocket, financing options.
Frequently asked questions
Can I market “painless” wisdom tooth removal?
Absolute-painless claims are inaccurate for most patients. Compliant framing acknowledges typical post-extraction experience while emphasizing sedation and pain management options.
How should I handle jaw surgery before/after?
HIPAA authorization for the specific use, typical-experience framing, time post-procedure, and case-complexity context. Jaw surgery outcomes are dramatically visible and require particular framing care.
Can I market TMJ surgery alternatives?
With accurate evidence framing. Conservative TMJ treatment has generally stronger evidence than surgical approaches; marketing should reflect the evidence state.
What about facial trauma marketing?
Facial trauma practice marketing is typically referral-based rather than direct-to-consumer. Marketing emphasis is usually on capability and credentialing.
How do I market in-office IV sedation?
Accurately reflect state licensing for the sedation level, safety protocols, and appropriate candidacy. Avoid safety absolutes.
What documentation should OMS practices maintain?
Board certification documentation, sedation licensing documentation, outcome tracking if using data in marketing, patient authorizations for surgical before/after imagery, and standard healthcare marketing records.
Built for this exact problem
Scan your clinic's content before regulators do.
RegenCompliance checks every word of your marketing against live FDA and FTC enforcement data - and rewrites violations automatically. A 30-second scan can save a $50,000–$5M regulatory response.
Related in the platform
Weekly compliance brief
One email a week. New enforcement actions, rule changes, and tactical fixes. No spam, unsubscribe anytime.
Keep reading
Compounded GLP-1 Marketing Compliance in 2026: What Changed When the Shortage List Closed
When the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for routine 503A compounding narrowed. Your existing compounded-GLP-1 marketing was probably written for the old posture. Here is the 2026 rewrite.
Read articleKetamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter
Most ketamine clinic marketing problems are not exotic - they are six or seven repeated phrases that the FDA October 2023 communication and 2024 enforcement actions have already singled out. This guide focuses on the IV ketamine for depression use case and rewrites the patterns that get clinics in trouble.
Read articleNAD+ IV Therapy Marketing and the FDA Position: What Actually Has Approval, What Does Not, and How to Word It
Most NAD+ IV therapy marketing trouble is upstream of the FTC longevity-claim issue. It is the quiet implication that NAD+ has some kind of FDA status it does not have. Here is the actual FDA position and how to word a NAD+ program page around it.
Read article